These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30231851)

  • 21. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
    Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
    Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
    Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
    Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C; Dengler T; Hack MA; Ladenburger S; Lehmkuhl HB
    Transplant Proc; 2013; 45(6):2387-92. PubMed ID: 23953553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study.
    Ying T; Wong G; Lim W; Kanellis J; Pilmore H; Campbell S; Masterson R; Walker R; O'Connell P; Russ G; Chadban S
    Am J Transplant; 2018 Dec; 18(12):2977-2986. PubMed ID: 29802791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
    Budde K; Lehner F; Sommerer C; Reinke P; Arns W; Eisenberger U; Wüthrich RP; Mühlfeld A; Heller K; Porstner M; Veit J; Paulus EM; Witzke O;
    Am J Transplant; 2015 Jan; 15(1):119-28. PubMed ID: 25521535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants?
    Choi JY; Kwon OJ
    Transplant Proc; 2013 Oct; 45(8):2892-8. PubMed ID: 24156999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
    de Fijter JW; Holdaas H; Øyen O; Sanders JS; Sundar S; Bemelman FJ; Sommerer C; Pascual J; Avihingsanon Y; Pongskul C; Oppenheimer F; Toselli L; Russ G; Wang Z; Lopez P; Kochuparampil J; Cruzado JM; van der Giet M;
    Am J Transplant; 2017 Jul; 17(7):1853-1867. PubMed ID: 28027625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.
    Kälble F; Seckinger J; Schaier M; Morath C; Schwenger V; Zeier M; Sommerer C
    Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28581202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppression and Post-transplant Hyperglycemia.
    Montero N; Pascual J
    Curr Diabetes Rev; 2015; 11(3):144-54. PubMed ID: 25824238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
    Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of posttransplant diabetes mellitus on graft function in autosomal dominant polycystic kidney disease patients after kidney transplantation.
    Pietrzak-Nowacka M; Safranow K; Dziewanowski K; Debska-Slizień A; Głyda M; Gołembiewska E; Jankowska M; Nowosiad M; Rutkowski B; Ciechanowski K
    Ann Acad Med Stetin; 2008; 54(1):41-8. PubMed ID: 19127808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion From Steroid to Everolimus in Maintenance Kidney Transplant Recipients With Posttransplant Diabetes Mellitus.
    Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
    Exp Clin Transplant; 2019 Feb; 17(1):47-51. PubMed ID: 29911959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study.
    Gnatta D; Keitel E; Heineck I; Cardoso BD; Rodrigues AP; Michel K; Garcia VD
    Transplant Proc; 2010 Mar; 42(2):475-8. PubMed ID: 20304169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post transplant diabetes mellitus in live related renal allograft recipients: a single centre experience.
    Saxena S; Dash SC; Guleria S; Mittal R; Agarwal SK; Tiwari SC; Mehta SN
    J Assoc Physicians India; 1996 Jul; 44(7):472, 477-9. PubMed ID: 9282609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
    Vincenti F; Rostaing L;
    Contemp Clin Trials; 2005 Feb; 26(1):17-24. PubMed ID: 15837449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.